-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical Group, has been awarded the title of “Meritorious Entrepreneur.”
Category:
Time：2022-11-02
On November 1, the 15th CPHI—China Health Industry (International) Ecosystem Conference, themed “Building a Circle of Shared Value for Patients—Dual-Drive Development Fuels New Growth in the Health Industry,” kicked off grandly in Bo'ao, Hainan. Su Xuejun, Chairman of Shijiazhuang Siyao Group, was honored with the title of “Meritorious Entrepreneur.”
On November 1, the 15th CPHI—China Health Industry (International) Ecology Conference, themed “Building a Circle of Patient Value: Dual-Drive Development Fuels New Growth in the Health Industry,” kicked off grandly in Bo'ao, Hainan.
In tribute to the entrepreneurial community of China’s health industry, whose spirit of entrepreneurship continues to shine brightly, the conference organizing committee has specially established the “Distinguished Entrepreneur” award. Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical Group, has been honored with the title of “Distinguished Entrepreneur.” In recent years, Shijiazhuang Fourth Pharmaceutical Group has anchored itself in a new stage of development, implemented new development concepts, and constructed a new development pattern. By benchmarking against industry leaders and taking proactive measures, the group has focused on cutting-edge industries and market demands, actively building a strategic high ground centered on innovation-driven growth. As a result, the company has gradually perfected and enhanced its industrial chain, creating a new operational model characterized by comprehensive and well-integrated supply chains. This has enabled the group to embark on an innovative path of high-quality development, making it a vital force in the innovation and advancement of the pharmaceutical industry. Today, Shijiazhuang Fourth Pharmaceutical Group has become one of China’s top 100 pharmaceutical enterprises and a nationally recognized demonstration enterprise for technological innovation.
It is reported that, as a long-established industry ecosystem conference, the CPHI Conference has been successfully held for fifteen sessions since 2008. To date, the CPHI Conference has integrated a variety of functions—including forward-looking insights and information exchange, strategic cooperation and communication, high-end industry image promotion, and cross-sectoral integration—into one platform. Guided by the CPHI spirit of “responsibility and commitment,” the conference promotes mainstream values in China’s health industry and leads industrial transformation, innovation, and ecological integration.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license